BNIGF (Beroni Group) 10-Year RORE % : 0.00% (As of Jun. 2024)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BNIGF Beroni Group Ltd BNIGF
4 GF Score
Price $0.01
View Full Analysis

What is Beroni Group 10-Year RORE %?

Beroni Group BNIGF 4 10-Year RORE % is 0.00 as of Jun. 2024. GuruFocus rates BNIGF with a GF Score™ of 4/100.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Beroni Group does not have enough data to calculate 10-Year RORE %.


Beroni Group  (OTCPK:BNIGF) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Beroni Group 10-Year RORE % Related Terms


Beroni Group 10-Year RORE % Historical Data

* Premium members only.

The historical data trend for Beroni Group's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beroni Group 10-Year RORE % Chart

Beroni Group Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
10-Year RORE %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Beroni Group Semi-Annual Data
Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BNIGF vs PNXP, CRYM, GCAN: 10-Year RORE % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Beroni Group's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Beroni Group 10-Year RORE % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Beroni Group's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Beroni Group's 10-Year RORE % falls into.


BNIGF
4GF Score
Beroni Group Ltd BNIGF
10-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beroni Group 10-Year RORE % Calculation

Beroni Group's 10-Year RORE % for the quarter that ended in Jun. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( - )/( - )
=/
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2024 and 10-year before.

Frequently Asked Questions Learn more about 10-Year RORE % →
What does a 10-Year RORE % of 0.00 mean?
Beroni Group (BNIGF) has a 10-Year RORE % of 0.00 as of Jun. 2024. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Beroni Group and its competitors.
Is Beroni Group's 10-Year RORE % too high?
Beroni Group's current 10-Year RORE % is 0.00. Overall, Beroni Group has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Beroni Group's 10-Year RORE % compare to PNXP and CRYM?
Beroni Group's 10-Year RORE % of 0.00 can be compared against companies in the Drug Manufacturers industry. The industry median 10-Year RORE % is 6.38. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 10-Year RORE % for a Drug Manufacturers company?
The median 10-Year RORE % among Drug Manufacturers companies is 6.38, based on 669 companies in the industry. Companies in the top quartile (top 25%) have a 10-Year RORE % significantly above this median, while those in the bottom quartile fall well below. However, 10-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 10-Year RORE % mean?
A high 10-Year RORE % can signal that a stock is expensive relative to its fundamentals. 10-Year RORE % shows how much a company earns by reinvesting its retained earnings in 10-year. View historical data on Beroni Group and its competitors. For the Drug Manufacturers industry, the median 10-Year RORE % is 6.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beroni Group's current 10-Year RORE % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beroni Group stock overvalued right now?
Beroni Group (BNIGF) has a current 10-Year RORE % of 0.00. The current 10-Year RORE % is 0.00. Beroni Group's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 10-Year RORE % calculated?
10-Year RORE % is calculated from a company's financial statements. For Beroni Group (BNIGF), the current 10-Year RORE % is 0.00 as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Beroni Group Business Description

Address 175 Pitt Street, Level 16, Sydney, NSW, AUS, 2000
Beroni Group Ltd is an Australia based company engaged in the sales of smoking control product (NicoBloc), air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics and viral diagnostic kits and also investing in the research and development of oncology drugs and therapies. It has organized its business into four core business areas: cell therapies, developing new anticancer drugs, an e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Geographically, the company operates in China.
4GF Score

Get the complete analysis for BNIGF

10-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price